Skip to main content

Advertisement

SpringerLink
Log in

Molecular lesions in colorectal cancer: impact on prognosis?

Original data and review of the literature

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease. Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance.

Discussion

One also hopes to derive improved prognostic factors from the clarification of the molecular pathogenesis. Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors. Despite a multitude of suggested molecular candidate markers none of these changes has yet been able enter the everyday life of the clinic. However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma.

Conclusion

Considering also our own findings, this review presents the latest developments in the scientific discussion of the tumor suppressor/oncogenes p53, k-ras, and DCC, biochemical determinants of the 5-fluorouracil metabolism, and defects of the DNA repair system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990. Springer, Berlin Heidelberg New York

  2. Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics. CA Cancer J Clin 47:5–27

    CAS  PubMed  Google Scholar 

  3. Dukes CE, Bussey HJR (1958) The spread of rectal cancer and its effect on prognosis. Br J Cancer 12:309–320

    CAS  Google Scholar 

  4. Fielding LP (1986) Clinical-pathologic staging of large bowel cancer. Lancet 45:8–30

    Google Scholar 

  5. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358

    CAS  PubMed  Google Scholar 

  6. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection for stage III colon carcinoma: a final report. Ann Intern Med 122:321–326

    CAS  PubMed  Google Scholar 

  7. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767

    PubMed  Google Scholar 

  8. Fearon ER (1995) Molecular genetics of colorectal cancer. Ann N Y Acad Sci 768:101–110

    CAS  PubMed  Google Scholar 

  9. Jen J, Kim H, Piantadosi S, Liu ZF, Liu ZF, Levitt RC, Sistonen P, et al (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221

    CAS  PubMed  Google Scholar 

  10. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453–456

    CAS  PubMed  Google Scholar 

  11. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318–1327

    Article  CAS  PubMed  Google Scholar 

  12. Chang F, Syrjanen S, Syrjanen K (1995) Implications of the p53-tumor-suppressor gene in clinical oncology. J Clin Oncol 4:1009–1022

    Google Scholar 

  13. Pereira H, Silva S, Juliao R, Garcia P, Perpetua F, et al (1997) Prognostic markers for colorectal cancer: expression of p53 and bcl2. World J Surg 21:210–213

    Article  CAS  PubMed  Google Scholar 

  14. Smith DR, Ji CY, Goh HS (1996) Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74:216–223

    Google Scholar 

  15. Soong R, Grieu F, Robbins P, et al (1997) p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405–1411

    CAS  PubMed  Google Scholar 

  16. Elsaleh H, Powell B, McCaul K, et al (2001) P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343–1349

    CAS  PubMed  Google Scholar 

  17. Esteller M, González S, Risques RA, et al (2001) k-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19:299–304

    CAS  PubMed  Google Scholar 

  18. Yang Y, Forslund A, Remotti, et al (2001) P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91:727–736

    Article  CAS  PubMed  Google Scholar 

  19. Gervaz P, Bouzourene H, Cerottini J-P, et al (2001) Dukes B colorectal cancer. Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44:364–373

    CAS  PubMed  Google Scholar 

  20. Diez M, Medrano M, Muguerza JM, et al (2000) Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res 20:3907–3912

    CAS  PubMed  Google Scholar 

  21. Gallego MG, Acenero MJ, Ortega S, et al (2000) Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 43:971–975

    Google Scholar 

  22. Bouzourene H, Gervaz P, Cerottini JP, et al (2000) P53 and k-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36:1008–1015

    Article  CAS  PubMed  Google Scholar 

  23. Nehls O, Klump B, Holzmann K, et al (1999) Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 85:2541–2548

    CAS  Google Scholar 

  24. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, et al (1999) Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593–599

    CAS  Google Scholar 

  25. Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al (1999) Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364–1374

    CAS  PubMed  Google Scholar 

  26. Tollenaar RAEM, van Krieken JHJM, van Slooten HJ, Bruinvels DJ, Nelemans KMJ, van den Broek LJ, et al (1998) Immunohistochemical detection of p53 and BCL-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 77:1842–1847

    CAS  PubMed  Google Scholar 

  27. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, et al (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149–1158

    CAS  PubMed  Google Scholar 

  28. Ilyas M, Hao X-P, Wilkinson K, et al (1998) Loss of bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 43:383–387

    CAS  PubMed  Google Scholar 

  29. Wiggenraad R, Tamminga R, Blok P, et al (1998) The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 41:29–35

    CAS  PubMed  Google Scholar 

  30. Caldes T, Iniesta P, de Juan C, et al (1998) Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer. Oncology 55:249–257

    Article  CAS  PubMed  Google Scholar 

  31. Starzynska T, Bromley M, Marlicz K, Roberts SA, Ucinski M, Stern PL (1997) Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepat 9:183–186

    Google Scholar 

  32. Maeda K, Chung Y-S, Kang S-M, et al (1997) Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74:310–315

    Article  CAS  PubMed  Google Scholar 

  33. Poller DN, Baxter KJ, Shepherd NA (1997) P53 and RB1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 75:87–93

  34. Bhatavdekar JM, Patel DD, Ghosh N, et al (1997) Coexpression of bcl-2, c-myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40:785–790

    CAS  PubMed  Google Scholar 

  35. Baretton GB, Diebold J, Christoforis G, et al (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77:255–264

    Article  CAS  PubMed  Google Scholar 

  36. Flamini G, Curigliano G, Ratto C, et al (1996) Prognostic significance of cytoplasmatic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer 32A:802–806

    Article  CAS  PubMed  Google Scholar 

  37. Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al (1996) P53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14:2696–2701

    CAS  PubMed  Google Scholar 

  38. Leahy DT, Salman R, Mulcahy H, et al (1996) Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180:364–370

    Article  CAS  PubMed  Google Scholar 

  39. Mulder JWR, Baas IO, Polak MM, Goodman SN, Offerhaus GJA (1995) Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 71:1257–1262

    Google Scholar 

  40. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, et al (1995) Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647–652

    CAS  PubMed  Google Scholar 

  41. Diez M, Enriquez JM, Camunas J, et al (1995) Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol 21:635–639

    CAS  PubMed  Google Scholar 

  42. Grewal H, Guillem JG, Klimstra DS, et al (1995) P53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis Colon Rectum 38:1176–1181

    CAS  PubMed  Google Scholar 

  43. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M (1994) Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70:293–296

    CAS  PubMed  Google Scholar 

  44. Bosari S, Viale G, Bossi P, et al (1994) Cytoplasmatic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681–687

    CAS  PubMed  Google Scholar 

  45. Morrin M, Kelly M, Barrett N, Delaney P (1994) Mutations of ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35:1627–1631

    CAS  PubMed  Google Scholar 

  46. Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT (1994) Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 37:527–534

    CAS  PubMed  Google Scholar 

  47. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, et al (1994) P53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12:2043–2050

    CAS  PubMed  Google Scholar 

  48. Tanaka M, Omura K, Watanabe Y, Oda Y, Nakanishi I (1994) Prognostic factors of colorectal cancer: k-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 57:57–64

    CAS  PubMed  Google Scholar 

  49. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazaki I (1993) p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68:399–402

    CAS  PubMed  Google Scholar 

  50. Bell S, Scott N, Cross D, Sagar P, Lewis FA, Blair E, et al (1993) Prognostic value of p53 overexpression and c-ki-ras gene mutations in colorectal cancer. Gastroenterology 104:57–64

    CAS  PubMed  Google Scholar 

  51. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P (1991) P53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319

    CAS  PubMed  Google Scholar 

  52. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, et al (1992) Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 66:758–764

    Google Scholar 

  53. Rosty C, Chazal M, Etienne M-C, et al (2001) Determination of microsatellite instability, p53 and k-ras mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer 95:162–167

    Google Scholar 

  54. Bleeker WA, Hayes VM, Karrenbeld A, et al (2001) Prognostic significance of k-ras and p53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum 44:358–363

    CAS  PubMed  Google Scholar 

  55. Soong R, Powell B, Elsaleh H, et al (2000) Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36:2053–2060

    Article  CAS  PubMed  Google Scholar 

  56. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA, et al (2000) P53 tumor supressor gene mutations predict decreased survival with sporadic colorectal carcinoma. Cancer 88:1814–1819

    Article  CAS  PubMed  Google Scholar 

  57. Liang JT, Cheng YM, Chang KJ, Chien CT, Hsu HC (1999) Reappraisal of k-ras and p53 gene mutations in the recurrence of Dukes B2 rectal cancer after curative resection. Hepatogastroenterology 46:830–837

  58. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al (1999) P53 and k-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17:1375–1381

    CAS  PubMed  Google Scholar 

  59. Hardingham JE, Butler WJ, Roder D, Dobrovic A, Dymock RB, Sage RE, et al (1998) Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 42:669–672

    CAS  PubMed  Google Scholar 

  60. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al (1994) Association of p53 mutations with short term survival in colorectal cancer. Gastroenterology 106:42–48

    CAS  PubMed  Google Scholar 

  61. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12

    CAS  PubMed  Google Scholar 

  62. Dix B, Robbins P, Carello A, House A, Iacopetta B (1994) Comparison of p53 gene mutation and protein overexpression in colorectal carcinoma. Br J Cancer 70:585–590

    Google Scholar 

  63. Wynford-Thomas D (1992) P53 in tumor pathology: can we trust immunocytochemistry? J Pathol 166:329

  64. Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779–827

    CAS  PubMed  Google Scholar 

  65. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB (1996) k-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16:3839–3844

    CAS  PubMed  Google Scholar 

  66. Font A, Abad A, Monzo M, Sanchez JJ, Guillot M, Manzano JL, et al (2001) Prognostic value of k-ras mutations and allelic imbalance of chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 44:549–557

    CAS  PubMed  Google Scholar 

  67. Samowitz WS, Curtin K, Schaffer D, et al (2000) Relationship of Ki-ras mutations in colon cancer to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9:1193–1197

    CAS  PubMed  Google Scholar 

  68. Kressner U, Bjorheim J, Westring S (1998) ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34:518–521

    Article  CAS  PubMed  Google Scholar 

  69. Andreyev HJNA, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90:675–684

    Article  CAS  PubMed  Google Scholar 

  70. Elnatan J, Goh HS, Smith DR (1996) C-ki-ras activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 32A:491–497

    Article  CAS  PubMed  Google Scholar 

  71. Kastrinakis WV, Ramchurren N, Maggard M, Steele G, Summerhayes IC (1995) k-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 130:9–14

    CAS  PubMed  Google Scholar 

  72. Finkelstein SD, Sayegh R, Bakker A, Swalsky P (1993) Determination of tumor aggressiveness in colorectal cancer by k-ras-2 analysis. Arch Surg 128:526–532

    CAS  PubMed  Google Scholar 

  73. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M (1987) Detection of high incidence of k-ras oncogenes during human colon tumorigenesis. Nature 327:298–303

    CAS  Google Scholar 

  74. Capella G, Cronauer-Mitra S, Peinado M, Perucho M (1991) Frequency and spectrum of mutations at codon 12 and 13 of the c-k-ras gene in human tumors. Environ Health Perspect 93:125–131

    CAS  PubMed  Google Scholar 

  75. Fearon E (1993) k-ras gene mutation as a pathogenic and diagnostic marker in human cancer. J Natl Cancer Inst 85:1978–1981

    CAS  PubMed  Google Scholar 

  76. Fearon ER, Cho KR, Nigro JM, et al (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49–56

    CAS  PubMed  Google Scholar 

  77. Cho KR, Fearon ER (1995) DCC: linking tumor suppressor genes and altered cell surface interactions in cancer? Eur J Cancer 31A:1055–1060

  78. Itoh F, Hinoda Y, Ohe M, et al (1993) Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer 53:260–263

    Google Scholar 

  79. Lino H, Fukayama M, Maeda Y, et al (1994) Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 73:1324–1331

    CAS  PubMed  Google Scholar 

  80. Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK (1995) The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 10:1581–1586

    CAS  PubMed  Google Scholar 

  81. Jernvall P, Mäkinen MJ, Karttunen TJ, Mäkelä J, Vihko P (1999) Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 79:903–908

    Google Scholar 

  82. Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR (1998) Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 114:1188–1195

    CAS  PubMed  Google Scholar 

  83. Martinez-Lopez E, Abad A, Font A, et al (1998) Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114:1180–1187

    CAS  PubMed  Google Scholar 

  84. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16:427–433

    Google Scholar 

  85. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206

    Article  CAS  PubMed  Google Scholar 

  86. Fazeli A, Dickinson SL, Hermiston ML, et al (1997) Phenotype of mice lacking functional deleted in colorectal cancer (DCC) gene. Nature 386:796–804

    Google Scholar 

  87. Gotley DC, Reeder JA, Fawcett J, et al (1995) The deleted in colorectal cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene 13:787–795

    Google Scholar 

  88. Hahn SA, Schutte M, Shamshul Hoque ATMS, et al (1996) DPC4: a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353

    CAS  PubMed  Google Scholar 

  89. Eppert K, Scherer SW, Ozcelik H, et al (1996) MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543–552

    CAS  Google Scholar 

  90. Sun XF, Rütten S, Zhang H, Nordenskjöld B (1999) Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 17:1745

    CAS  PubMed  Google Scholar 

  91. Halling KC, French AJ, McDonnell SK, et al (1999) Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 15:1295–1303

    Article  Google Scholar 

  92. Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H, Furukawa K (1998) Reduced expression of deleted colorectal carcinoma protein in established colon cancers. Br J Cancer 77:466–471

    Google Scholar 

  93. Reymond MA, Dworak O, Remke S, Hohenberger W, Kirchner T, Köckeling F (1998) DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 41:755–760

    CAS  PubMed  Google Scholar 

  94. Cohn KH, Ornstein DL, Wang F, et al (1997) The significance of allelic deletions and aneuploidy in colorectal carcinoma. Cancer 79:233–244

    Article  CAS  PubMed  Google Scholar 

  95. Shibata D, Reale MA, Lavin P, et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727–1735

    PubMed  Google Scholar 

  96. Kato M, Ito Y, Kobayashi S, Isono K (1996) Detection of DCC and ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 77:1729–1735

    CAS  PubMed  Google Scholar 

  97. Young J, Buttenshaw R, Butterworth L, et al (1994) Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers. Oncogene 9:1053–1056

    CAS  PubMed  Google Scholar 

  98. Beverley SM, Ellenberger TE, Cordingly JS (1984) Primary structure the gene encoding the bifunctional dihydrofolate reduction-thymidylate synthase of Leishmania major. Proc Natl Acad Sci USA 83:2584–2589

    Google Scholar 

  99. Conrad AH, Ruddle FH (1972) Regulation of thymidylate synthase activity in cultured mammalian cells. J Cell Sci 10:471–486

    CAS  PubMed  Google Scholar 

  100. Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-Fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855–1864

    CAS  PubMed  Google Scholar 

  101. Copur S, Aiba K, Drake JC, et al (1995) Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49:1419

    Article  CAS  PubMed  Google Scholar 

  102. Leichman L, Lenz HJ, Leichman CG, et al (1995) Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31:1306–1310

    Article  Google Scholar 

  103. YamachikaT, Nakanishi H, Inada KI, Tsukamoto T, Kato T, Fukushima M, et al (1998) A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82:70–77

    Article  PubMed  Google Scholar 

  104. Edler D, Kressner U, Ragnhammar, Johnston PG, Magnusson I, Glimelius B, et al (2000) Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 6:488–492

    CAS  PubMed  Google Scholar 

  105. Cascinu S, Graziano F, Valentini, Catalano V, Giordani P Stacciolo MP, et al (2001) Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12:239–244

    Article  CAS  PubMed  Google Scholar 

  106. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A (2000) Thymidylate synthase protein expression in primary colorectal cancer compared with corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6:4797–4802

    CAS  PubMed  Google Scholar 

  107. Cascinu S, Catalano V, Aschele C, Barni S, Debernadis D, Gallo L, et al (2000) Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann Oncol 11:1053–1056

    Article  CAS  PubMed  Google Scholar 

  108. Van Triest B, Pinedo HM, Blaauwgeers JLG, van Diest PJ, Schoenmakers PS, Voorn DA, et al (2000) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063–1072

    PubMed  Google Scholar 

  109. Edler D, Hallström M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2000) Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease free-survival and overall survival in rectal cancer. Clin Cancer Res 6:1378–1384

    CAS  PubMed  Google Scholar 

  110. Aschele C, Debernardis D, Tunesi G, Bandelloni R, Cascinu S, Catalano V, et al (2000) Schedule-dependent correlation between the level of thymidylate synthase (TS) protein expression and clinical response to different 5-fluorouracil (5-FU) regimens in advanced colorectal cancer. Proc Am Soc Clin Oncol 19:251a

    Google Scholar 

  111. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, et al (2000) Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560–567

    Google Scholar 

  112. Davies MM, Johnston PG, Kaur S, Allen-Mersh TG (1999) Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5:325–328

    CAS  PubMed  Google Scholar 

  113. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al (1999) Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17:1760–1772

    CAS  PubMed  Google Scholar 

  114. Cascinu S, Aschele C, Barni S, Debernadis D, Baldo C, Tunesi G, et al (1999) Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5:1996–1999

    CAS  PubMed  Google Scholar 

  115. Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75:903–909

    Google Scholar 

  116. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark M, Drake JC, et al (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640–2647

    CAS  PubMed  Google Scholar 

  117. Lenz H-J, Hayashi K, Solonga D, Danenberg KD, Danenberg PV, Metzger R, et al (1998) P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243–1250

    CAS  PubMed  Google Scholar 

  118. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223–3229

    CAS  PubMed  Google Scholar 

  119. Kornmann M, Link KH, Lenz H-J, Pillasch J, Metzger R, Butzer U, et al (1997) Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118:29–35

    Article  CAS  Google Scholar 

  120. Gorlick R, Metzger R, Danenberg KD, Solonga D, Miles JS, Longo GSA, et al (1998) Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16:1465–1469

    Google Scholar 

  121. Sanguedolce R, Vultaggio G, Sanguedolce F, Modica G, Li Volsi F, Diana G, et al (1998) The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18:1515–1520

    CAS  PubMed  Google Scholar 

  122. Moghaddam A, Zang HAT, Fan TP, et al (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:988–1002

    PubMed  Google Scholar 

  123. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110–1117

    CAS  PubMed  Google Scholar 

  124. Metzger R, Danenberg K, Leichman CG, Solonga D, Schwartz EL, Wadler S, et al (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371–2376

    CAS  PubMed  Google Scholar 

  125. Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, et al (2000) Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 88:42–49

    Article  CAS  PubMed  Google Scholar 

  126. Naguib FNM, El Kouni AM, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic tissues. Cancer Res 45:5405

    CAS  PubMed  Google Scholar 

  127. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203–2206

    CAS  PubMed  Google Scholar 

  128. Solonga D, Danenberg KD, Johnson M, et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327

    CAS  PubMed  Google Scholar 

  129. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260:812–816

    CAS  PubMed  Google Scholar 

  130. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M, et al (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561

    CAS  PubMed  Google Scholar 

  131. Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Järvinen H, et al (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260:810–812

    CAS  PubMed  Google Scholar 

  132. Aaltonen LA, Peltomaki P, Mecklin JP, Järvinen H, Jass JR, Green JS, et al (1994) Replication errors in benign and malignant tumors from hereditary non-polyposis colorectal cancer patients. Cancer Res 54:1645–1648

    CAS  PubMed  Google Scholar 

  133. Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkänen L, et al (1993) Genomic instability in colorectal cancer: relationship of clinicopathological variables and family history. Cancer Res 53:5849–5852

    CAS  PubMed  Google Scholar 

  134. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816–819

    PubMed  Google Scholar 

  135. Kim H, Jen J, Vogelstein B, Hamilton SR (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148–156

    CAS  PubMed  Google Scholar 

  136. Möslein G, Testet DJ, Lindor NM, Honchel R, Cunningham JM, French AJ (1996) Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 5:1245–1252

    CAS  PubMed  Google Scholar 

  137. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535–1549

    CAS  PubMed  Google Scholar 

  138. Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, et al (2001) Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 159:297–304

    CAS  PubMed  Google Scholar 

  139. Ward R, Meagher A, Tomlinson I, O'Connor T, Norrie M, Wu R, et al (2001) Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 48:821–829

    CAS  PubMed  Google Scholar 

  140. Gafà R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, et al (2000) Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89:2025–2037

    Article  CAS  PubMed  Google Scholar 

  141. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197–1202

    Article  CAS  PubMed  Google Scholar 

  142. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H (2000) Microsatellite instability as a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119:921–928

    CAS  PubMed  Google Scholar 

  143. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745–1750

    PubMed  Google Scholar 

  144. Gonzalez-Garcia I, Moreno V, Navarro M, Marti-Rague J, Marcuello E, Benasco C, et al (2000) Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 92:544–549

    Article  CAS  PubMed  Google Scholar 

  145. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69–77

    CAS  PubMed  Google Scholar 

  146. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Chien CT, Wang SM (1999) Clinicopathological and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection. Hepatogastroenterology 46:883–890

    Google Scholar 

  147. Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, Kristjansson AK, Ragnarsson G, Jonasson JG, et al (1999) Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 19:1821–1826

    CAS  PubMed  Google Scholar 

  148. Jernvall P, Mäkinen MJ, Karttunen TJ, Mäkelä J, Vihkoo P (1999) Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 35:197–201

    Article  CAS  PubMed  Google Scholar 

  149. Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Pahlman L, et al (1999) Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 81:190–193

    Article  CAS  PubMed  Google Scholar 

  150. Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP, et al (1999) Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 188:14–17

    Article  CAS  PubMed  Google Scholar 

  151. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al (1996) Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12:2641–2649

    CAS  PubMed  Google Scholar 

  152. Schmoll HJ, Büchele T, Grothey A, Dempke W (1999) Where do we stand with 5-FU? Semin Oncol 26:589–605

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, University Hospital, Otfried-Müller-Strasse 10, 72076, Tübingen, Germany

    B. Klump, O. Nehls, T. Okech, C.-J. Hsieh, V. Gaco, F. S. Gittinger & M. Gregor

  2. Institute of Pathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

    M. Sarbia

  3. Institute of Pathology, Hospital Aschaffenburg, Aschaffenburg, Germany

    F. Borchard

  4. Institute of Pathology, University Hospital Tübingen, Tübingen, Germany

    A. Greschniok

  5. Department of Surgery, Evangelisches Hospital Düsseldorf, Düsseldorf, Germany

    H. H. Gruenagel

  6. Department of Internal Medicine, Central Hospital Bremen-Ost, Bremen, Germany

    R. Porschen

Authors
  1. B. Klump
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Nehls
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Okech
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C.-J. Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Gaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. S. Gittinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Sarbia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Borchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Greschniok
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. H. Gruenagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Porschen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Gregor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Klump.

Additional information

B. Klump and O. Nehls contributed equally to this manuscript

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klump, B., Nehls, O., Okech, T. et al. Molecular lesions in colorectal cancer: impact on prognosis? . Int J Colorectal Dis 19, 23–42 (2004). https://doi.org/10.1007/s00384-003-0499-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-003-0499-7

Keywords

Search

Navigation